Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous Imaging of Tumor Hypoxia and Proliferation in High-Grade Glioma
NCT04309552Phase 1Suspended
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluoromisonidazole and fluorothymidine F-18 in glioma, sponsored by Weill Cornell Medicine. Primary endpoints: Quantitation of tumor hypoxia (FMISO) by measuring Dyn PET at 1 year and Quantitation of proliferation (FLT) by measuring Dyn PET at 1 year. Started Feb 2021; status: suspended.
02
Drugs
fluoromisonidazolefluorothymidine F-18
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04309552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309552.